
# Artificial intelligence in drug discovery and development
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577280/

## Authors (@slack): Logy Khaled (@Logy), Tawfek Ahmed (@Tawfekahmed25), Uwaisu Nura (@uwais), Lewis Karani (@Karani)

# GithubRepo:
https://github.com/lewis-karani/HackBio-2024/edit/main/Stage1.md

Artificial Intelligence (AI) is revolutionizing the pharmaceutical industry, fundamentally transforming every stage of drug discovery and development. AI's capacity to process vast datasets and identify patterns that elude human analysis is accelerating the identification of potential drug candidates, thereby shortening the traditionally lengthy and costly drug development process. The applications of AI in drug discovery today are vast(Paul D. et al., 2020).

[68747470733a2f2f6c68372d72742e676f6f676c6575736572636f6e74656e742e636f6d2f646f63737a2f41445f346e5864337173576f4637797345324c41537532765445477a3743376a5966644d69636a676e65306c43745056435a4135453351582d5a722d544b6f76447931347a676b6d61487](https://github.com/user-attachments/assets/7db1d35b-3654-4a0d-857c-af524789cc17)


The integration of AI in drug discovery has enabled the identification of hit and lead compounds with unprecedented speed(Mak K. et al.,2019). Advanced algorithms, including machine learning (ML) models like deep neural networks (DNNs), can predict the biological activity of compounds, thereby refining the drug screening process and enhancing the accuracy of target validation. This is crucial in an industry where nine out of ten therapeutic molecules fail during clinical trials, often in the later, more expensive stages​(Beneke F. et al., 2019)​(Kalyane D. et al.,2020).

Moreover, AI is instrumental in drug repurposing, a strategy that finds new therapeutic uses for existing drugs. This approach, combined with AI's predictive capabilities, holds promise for addressing complex diseases such as cancer, where AI models can predict synergistic drug combinations that might be more effective than current treatments​(Öztürk H, 2018). The application of AI extends beyond discovery, playing a significant role in the development phase. For instance, AI tools like QSAR models are being utilized to predict the physicochemical properties of drug molecules, which are critical for assessing a drug's pharmacokinetics and pharmacodynamics​(Karimi M., 2019).

In the realm of pharmaceutical manufacturing, AI is driving efficiency and precision. AI-powered automation tools, such as the Chemputer platform, are revolutionizing the synthesis and production processes by reducing the time required for molecule creation and ensuring batch-to-batch consistency. This not only speeds up production but also enhances the overall safety and quality of pharmaceutical products​(Rantaneej & Khinast, 2015)​(Chan H.S, 2019).

Drug efficacy depends on how well a molecule binds to its target protein or receptor. Without this interaction, the drug can't produce the desired therapeutic effect. However, if a drug binds to unintended targets, it can cause toxicity. Therefore, predicting drug-target binding affinity (DTBA) is crucial. AI-based methods help measure this affinity by either analyzing the chemical features of the drug and target or by comparing the similarity between them, assuming that similar drugs interact with similar targets.

However, the adoption of AI in the pharmaceutical industry is not without challenges. The implementation of AI requires access to large, high-quality datasets, which can be expensive and difficult to obtain. Additionally, there is a need for skilled personnel who can operate these advanced platforms and interpret the data they generate. Despite these hurdles, the potential benefits of AI are driving significant investment in the sector, with projections indicating that AI will generate billions in revenue for the pharmaceutical industry in the coming years​(Lambert M.J, 2019)​(Research & Markets., 2019).

The future of AI in pharmaceuticals is promising, with ongoing advancements likely to lead to more personalized and effective treatments. As AI continues to evolve, its integration into every aspect of drug discovery and development will likely become paramount, transforming how we understand and treat diseases.

# References
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021 Jan;26(1):80-93.
doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21. PMID: 33099022; PMCID: PMC7577280.

Beneke F., Mackenrodt M.-O. Artificial intelligence and collusion. IIC Int. Rev. Intellectual Property Competition Law. 2019;50:109–134.

Kalyane D. Artificial intelligence in the pharmaceutical sector: current scene and future prospect. In: Tekade Rakesh K., editor. The Future of Pharmaceutical Product Development and Research. Elsevier; 2020. pp. 73–107.

Mak K.-K., Pichika M.R. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today. 2019;24:773–780.

Öztürk H. DeepDTA: deep drug–target binding affinity prediction. Bioinformatics. 2018;34:i821–i829.

Karimi M. DeepAffinity: interpretable deep learning of compound–protein affinity through unified recurrent and convolutional neural networks. Bioinformatics. 2019;35(18):3329–3338. 

Rantanen J., Khinast J. The future of pharmaceutical manufacturing sciences. J. Pharm. Sci. 2015;104:3612–3638.

Chan H.S. Advancing drug discovery via artificial intelligence. Trends Pharmacol. Sci. 2019;40(8):592–604.

Research and Markets . Research and Markets; 2019. Global Growth Insight - Role of AI in the Pharmaceutical Industry 2018-2022: Exploring Key Investment Trends, Companies-to-Action, and Growth Opportunities for AI in the Pharmaceutical Industry.

Lamberti M.J. A study on the application and use of artificial intelligence to support drug development. Clin. Ther. 2019;41:1414–1426.
